On January 15, 2020, William D. Schwieterman, a member of the Board of Directors (the “Board”) of Mateon Therapeutics, Inc. (the “Company”), notified the Company of his resignation as a director, effective immediately. Mr. Schwieterman indicated that due to his current work obligations, he would be unable to give the proper time and attention to his service as a director of the Company’s Board. Mr. Schweiterman did not express any disagreements with the operations, policies or practices of the Company on any matters. On January 22, 2020, David Diamond, CPA, agreed to join the Board of the Company, and fill the vacancy created by Mr. Schwieterman’s resignation, on terms that are yet to be finalized. Mr. Diamond provides strategic guidance and operational oversight to CEOs and Board Directors in the Life Sciences industry. David has significant experience assisting management teams and board directors with capital financing and strategic business planning nationally and internationally. David has built strong relationships with Wall Street Bankers. He is the National Life Sciences and Technology Practice Lead at Mayer Hoffman McCann P.C. He has over 30 years of experience in both public accounting and industry.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâs Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.
ONCOTELIC THERAPEUTICS, INC. 
